HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2006.080762v1 53/4/790    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Dahl, C. Articles by Brøndum-Nielsen, K. Search for Related Content PubMed PubMed Citation Articles by Dahl, C. Articles by Brøndum-Nielsen, K. Related Collections Molecular Diagnostics and Genetics

A Homogeneous Assay for Analysis of FMR1 Promoter Methylation in Patients with Fragile X Syndrome

¹ Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; ² The Kennedy Institute-National Eye Clinic, Glostrup, Denmark; and ³ Wilhelm Johannsen Centre for Functional Genome Research, Department of Medical Biochemistry and Genetics, University of Copenhagen, Denmark;

^aaddress correspondence to this author at: The Kennedy Institute-National Eye Clinic, Gl. Landevej 7, DK-2600 Glostrup, Denmark; fax 45-43-43-11-30, e-mail kbn{at}kisoe.org

Abstract

Background: Fragile X syndrome is caused by the expansion of a CGG trinucleotide repeat at the 5' untranslated region of the fragile X mental retardation 1 gene (FMR1). When expanded to >200 repeats (full mutation), the repeat region and the adjacent promoter CpG island become hypermethylated, rendering FMR1 transcriptionally inactive. Conventional molecular diagnosis of fragile X syndrome involves determination of the CGG repeat number by Southern blot analysis.

Methods: A homogeneous methylation-specific melting curve analysis (MS-MCA) assay for methylation status of the FMR1 promoter region was developed on the LightCycler platform. Genomic DNA was treated with sodium bisulfite, and a region containing 8 CpG sites was amplified in the presence of SYBR Green I, using primers that do not differentiate between methylated and unmethylated FMR1 molecules. After amplification, the samples were melted at 0.05 °C/s, and fluorescence melting curves were recorded. We studied samples, previously characterized by Southern blot analyses, from 10 female and 10 male donors with normal numbers of CGG trinucleotide repeats, 9 male donors who were premutation carriers, 4 male donors who carried both a premutation and a full mutation, and 25 patients with fragile X syndrome.

Results: Samples from all 20 male patients with fragile X syndrome showed a high melting peak corresponding to fully methylated FMR1, whereas samples from healthy males showed a single low melting peak corresponding to unmethylated FMR1. Of 24 samples from affected males, 9 (38%) showed 2 melting peaks, suggesting that cellular methylation mosaicism is common in fragile X syndrome.

Conclusions: MS-MCA allows rapid and reliable identification of fragile X syndrome in male patients.

The following articles in journals at HighWire Press have cited this article:

				C. Dahl and P. Guldberg A ligation assay for multiplex analysis of CpG methylation using bisulfite-treated DNA Nucleic Acids Res., December 18, 2007; 35(21): e144 - e144. [Abstract] [Full Text] [PDF]

				C. Dahl and P. Guldberg High-Resolution Melting for Accurate Assessment of DNA Methylation Clin. Chem., November 1, 2007; 53(11): 1877 - 1878. [Full Text] [PDF]